According to a post on the FDA’s website, Novo Nordisk’s treatment of transthyretin amyloidosis, coramitug, was granted orphan designation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Biotech Alert: Searches spiking for these stocks today
- Unusually active option classes on open September 23rd
- Skye Bioscience comments on monlunabant Phase 2 top-line data
- Corbus Pharmaceuticals price target lowered to $40 from $85 at B. Riley
- Skye Bioscience should be bought on selloff, says Piper Sandler